Why Attend
Join the first ever conference series connecting human biotechs with the animal health industry.
Following the event's hugely successful launch in Boston, USA, Human Biotech & Animal Health Business Partnering Summit is now coming to Europe.
Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.
Benefits of the Animal Health industry to Biotechs:
Testimonials
"This was an excellent event. As a newbie to animal health this was an eye opener. Some great connections and introductions. I would highly recommend your conference. The right balance of networking and information. Thank you!"
Sean Ekins, CEO, COLLABORATIONS PHARMA
"This conference provided relevant information and has led to a potential collaboration. I thought the conference was well focused. It was time well spent. I learned a lot and had productive networking sessions. The concept of the confluence of Human Biomedical development and Animal health is integral to our business plan. Kalos looks to leverage its proof of concept work as well as safety and tox to create parallel product lines."
George Colberg, CEO, Kalos Therapeutics, Inc.
"A well organized conference that established a strong link between biotechnology innovation and potential veterinary uses.”
Michael G. Palfreyman, Director, R&D Advisory Board, PAFOS PHARMA LLC
WHO SHOULD ATTEND?
HUMAN BIOTECHNOLOGY
Chief Executive Officers, Chief Scientific Officers, Chief Business Officers and corporate leadership from human biotechs working on technologies in fields including but not limited to:
ANIMAL HEALTH
- Directors of External Innovation & Business Development from leading Animal Health Pharmaceutical and Nutrition Companies
- Market Intelligence and Consultancy Providers
INVESTMENT & SERVICE PROVIDERS
- Private Equity & Venture Capital Investors
- Investment Bankers & M&A advisors
- Legal Advisory
A sample of attendees from Boston 2018
Benefits of Attending
- Explore opportunities for generating non-dilutive income, validating and de-risking human research, and maximizing IP assets in our myth-busting case studies of human biotech and animal health partnerships.
- Forge relationships with animal health executives in pre-scheduled 1-on-1 meetings, and discuss research collaborations, deal-licensing and other business development opportunities.
- Discuss unmet medical needs in veterinary health, and learn how the regulatory road works, how the industry operates and which technologies are of interest to animal pharmaceutical and nutrition companies.
- Identify commercial potential in your translational technologies with investors and advisory firms specializing in the veterinary health industry.
Highlights from the Series
The Speakers
Chris Primiano
Chris is responsible for leading Karyopharm’s operations, business development and legal departments and has been with the Company since March 2014.
Prior to joining Karyopharm, Chris worked at multiple international law firms and led internal legal and business development departments. He was a Counsel at Wilmer Cutler Pickering Hale and Dorr LLP, a full-service multinational law firm, and he served as Vice President, Corporate Development, General Counsel and Secretary of GlassHouse Technologies, Inc., an information technology consulting company, where he led global legal operations and managed asset and subsidiary acquisition and sale activity. Chris began his career at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP, a global law firm focused on venture capital and the emerging technology marketplace.
Chris received a Bachelor of Arts in Political Economy and English from Georgetown University, a Master of Business Administration from the Boston College Carroll School of Management and a Juris Doctor from Boston College Law School.
Rüdiger Raue
Rüdiger Raue studied veterinary medicine at the Free University of Berlin (Germany), where he also obtained his Dr. med. vet. (PhD equivalent) in 2000. He spent five years as a post-doctoral fellow in Leipzig (Germany) working on molecular characterisation and engineering of avian viruses. During this time he qualified as a Veterinarian Specialist for Virology and earned certified qualifications in molecular biology and genetic engineering in animals. In 2005, he started his industrial career at Pfizer Animal Health in Sandwich (United Kingdom) as a member of the Analytical Sciences group in which he held various positions with increasing responsibilities. When the European R&D operations for Animal Health moved to Belgium in 2011, he became the head of the EU Analytical Sciences team. Rüdiger joined the External Innovation organisation within Zoetis R&D in March 2016. He is responsible for external collaborations and research alliances in Europe.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. With our singular focus on animal health, we strive to make our products, services, and people the most valued by our veterinarian and livestock producer customers around the world. For more information, please visit www.zoetis.com.
Remko van Leeuwen
Remko van Leeuwen has a medical background in the field of infectious diseases - and more than 25 years of drug development and clinical trial experience under his belt, both in the industry as well as in the academic arena. He knows both worlds inside out, have a large network, and therefore able to build bridges between them.
Remko founded Madam Therapeutics in 2011, as he wanted to do something to about the significant deficit in the development of novel antimicrobial compounds over the two decades. In the 7 years since it’s foundation, the company has matured into a near clinical stage biotech company that has developed a new generation of compounds that manage to knock out persister cells residing in bacterial biofilms. As highlighted in a recent editorial comment on the website of Science1, this represents the first published demonstration of the killing of such persister cells, which is anticipated to have great potential to treat patients with complicated infections.
In these 7 years, Remko has met many other entrepreneurs that are as motivated as he is to bring new antimicrobials to the market. At the same time, he also encountered a lot of sepsis and reluctance to make serious investments from professional investors and established companies in this field. He will share his experiences from the roller-coaster road to get his companies financed, and will share his ideas on how to improve ties between medical professionals and veterinarian to preserve the health and well-being of all species.
1. http://www.sciencemag.org/news/2018/01/powerful-new-weapon-against-drug-resistant-bacteria-was-inspired-human-body
Dr. Klaus Hellmann
Liana Steeghs
Liana Steeghs is CEO at Immuno Valley. She has an entrepreneurial spirit, is an excellent matchmaker and has a proven track record in acquisition of funding and establishing R&D partnerships in the field of infectious diseases. Before Immuno Valley, she worked for 15 years as a scientist in knowledge and applied technology institutes in the Netherlands and the UK. From her personal drive to contribute to the health of humans and animals, she specialized in bacterial vaccinology and immune mechanisms aiming at prevention of infectious diseases. Liana was trained in Biotechnology, followed by a PhD in Molecular Microbiology at Utrecht University. In addition, she holds a degree in Program management and completed the RSM Diploma programme in Business management and Leadership.
Michael Graz
Michael has 25 years of commercial, research and teaching experience in the life sciences, biotechnology and food processing sectors. Over this period of time he has held senior management, advisory and technical consultancy roles. He has managed turnaround situations in corporate environments, established startups and developed services in corporate and SME organisations and with clients who have included governmental and intergovernmental bodies. This has taken him to live on 4 continents and to work across 5. With 2 PhDs, numerous papers and international conference presentations, joint inventorship on 6 patents, Michael has a deep understanding of bacterial functioning and antimicrobial resistance in infectious diseases.
For the past 10 years he has been active in the diagnostics and biotech sectors in South Wales and in his last role achieved Orphan Designation from the FDA for an anti-virulence factor against Pseudomonas aeruginosa in CF patients. He is the Managing Director of Cardiff-based Q5 Healthcare, a life sciences company with a focus on developing rapid, point of care diagnostics to improve quality of life for patients with life changing bacterial infections.
Alessandro Della Chà
Italian (born 1963), has been a Board Member of Cosmo Pharmaceuticals S.A. since 2006 and
is the CEO as of 27 March 2014.
Until 27 March 2014, he was senior partner at Studio Legale Edoardo Ricci e Associati, Milan,
where he specialized in company law, mergers and acquisitions. He joined the firm in 1988.
From 1987 to 1988 he was assistant of the central director for corporate matters at Fininvest
Group. From 1994 to 1998 he was director of II.PP.A.B. Milan (formerly ECA), a charitable
institution owning hospitals and specialized in elderly care.
Alessandro Della Chà has a degree in law from the University of Milan, Italy, and an LL.M. in
European Union commercial law from the University of Leicester, United Kingdom. He is a
lecturer in conferences and seminars held by universities and institutions on commercial and
company law issues.
Chris Hand
Dr Chris Hand has 30 years’ experience in the medical diagnostics industry in the development and commercialisation of in vitro diagnostic products. Chris co-founded the medical diagnostics company Cozart Bioscience Ltd and was Chief Executive of Cozart plc, following IPO on AIM in 2004, until October 2007 when the company was sold to Concateno plc for £65 million. Chris was a non-executive director of Concateno plc until its sale to US listed Alere Inc for £147m in August 2009 and stayed with the company as consultant until June 2010. Prior to founding Cozart, Chris was Director of Research for the European base of DPC (now part of Siemens Healthcare Solutions) developing a wide range of immunodiagnostic kits in a variety of formats.
Chris was a non-executive director of Advanced Computer Software plc, the AIM-listed leading software and IT services provider until the sale to Vista Private Equity for £750m in March 2015.
He has a BSc in Applied Biochemistry from Brunel University and a DPhil from the Faculty of Medicine, University of Oxford.
Mark Heffernan
Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.
Prior to Nexvet, he was also co-founder of an Irish biotechnology company, Opsona Therapeutics, focused on therapeutics for human inflammatory diseases where he raised US$50 million to commercialise research from Trinity College Dublin. Through his career, he has worked in research and business development in the USA, Asia Pacific and Europe.
The Agenda
Download 2018 Agenda
Venue
NH Amsterdam Zuid, Van Leijenberghlaan 221, 1082 GG Amsterdam, Netherlands
The NH Amsterdam Zuid hotel is located in Amsterdam’s Jewish quarter. It’s near the Zuidas business district, a trendy neighborhood packed with shops, restaurants and cafés, and a short tram or metro ride away from the bustling city center.
Event attendees can book discounted accommodation here:
http://www.nh-hotels.com/event/kisaco-research
Single occupation €189.90 per night (including breakfast, excluding tourism taxes).
Please book before 4th June to qualify for these rates.
If you would like to book additional nights at the hotel, outside of 18th June, please email Apana Bergtop: [email protected] and mention Kisaco Research.
Senior Event Partner
Networking Reception Host
Event Partner
Media Partners
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Book a Team to Save More!
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
Payment Terms for Animal Health Investment Europe:
- Please note that a £49 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in GBP
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Those offering consultancy or market intelligence services do not qualify for the Start-Up rate.
- PLEASE NOTE – no additional discounts are available on ‘Start-up Company’ pricing. Group discounts are ONLY available on ‘Delegate’ pricing.
- You can view our Cancellation Policy here.
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
